File No. CT/104/21-DCG(I)

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road New
Delhi - 110002 (Delhi) Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

सत्यमेव जयते

File No. CT/21/000104

To,

M/s. Eli Lilly and Company (India) Pvt. Ltd.,
Plot No. 92, Sector 32, Institutional Area,
Gurugram, Haryana (India) -122001.

Sir,

With reference to your application No GCT/CT04/FF/2021/27482 (GCT/104/21) dated 23/08/2021, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, "**EMBER-3: A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator's Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy", Protocol number: J2J-OX-JZLC Version 1.0, dated 15/March/2021** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) **The applicant shall submit EMBER phase 1a/1b (J2J-MC-JZLA) clinical study report to CDSCO.**
(ii) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
(iii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iv) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
(v) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
(vi) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the

Indian Council of Medical Research before enrolling the first subject for the trial;

(vii) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(viii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(ix) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(x) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(xi) all SAEs including death irrespective of its cause i.e. PD, should be reported as SAEs to CLA as per provision of NDCTR 2019 and any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(xii) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiv) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xvi) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvii) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xviii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xix) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

(xx) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

VENUGOPAL G SOMANI

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DRUGS CONTROLLER GENERAL (INDIA), pseudonym=8204c5ae81...8732c456d249073e55e953d9cb5b558748ee, st=[illegible], serialNumber=e97f241aa0c0bba41522525f..., cn=VENUGOPAL G SOMANI
Date: 2022.04.13 18:02:25 IST

(Dr. V.G. Somani)
Drugs Controller General (India)
Central Licencing Authority

Seal/Stamp

File No. CT/104/21-DCG(I)

FORM CT-06
(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1.The Central Licensing Authority hereby permits **M/s. Eli Lilly and Company (India) Pvt. Ltd., Sector 32, Plot No. 92, Gurgaon, Gurgaon (India) – 122001** to conduct clinical trial of the new drug or investigational new drug as per **Protocol number: J2J-OX-JZLC Version 1.0, dated 15/March/2021** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

VENUGOPAL G SOMANI
(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licencing Authority

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DRUGS CONTROLLER GENERAL INDIA, pseudonym=112046a34e21727bacb255748...48ee31 13c, postalCode=110002, st=DELHI, serialNumber=e97f041a4b0bba3152525ff ca0705074b4997e6b274f95c8d81cf282adeaf 5d, cn=VENUGOPAL G SOMANI
Date: 2022.04.13 18:02:35 +05'30'

Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	LY3484356
Therapeutic class:	selective estrogen receptor degraders SERD
Dosage form:	Tablets
Composition:	Purified Water = 1.0000 ml U.S.P .Inactive Magnesium Stearate -Extragranular = 5.3000 mg/tablet U.S.P. Inactive Croscarmellose Sodium -Extragranular = 26.5000 mg/tablet U.S.P. Inactive Hydroxypropyl Cellulose EXF = 15.9000 mg/tablet U.S.P. Inactive Croscarmellose Sodium = 21.2000 mg/tablets U.S.P. Inactive Microcrystalline Cellulose = 195.4400 mg/tablet U.S.P. Inactive LY3484356 tosylate = 256.6600 mg/tablet In House Specification Active
Indications:	Metastatic Breast Cancer

File No. CT/104/21-DCG(I)

Annexure:

Details of clinical trial site:

Names and address of clinical trial site	**Ethics committee details**	**Name of investigator**
Deenanath Mangeshkar Hospital & Research Centre, Erandawane, Pune-411004 Maharashtra, India	Institutional Ethics Committee -Lata Mangeshkar Medical Foundation's (IEC-LMMF), Deenanath Mangeshkar Hospital & Research Centre, Erandwame, Pune, 411004 Maharashtra ECR/15/Inst/Maha/2013/RR-19	Dr. Chetan Deshmukh
Government Medical College And Hospital Medical College Square Road, Nagpur-440003 Maharashtra, India	Institutional Ethics Committee, GMCH Nagpur, Institutional Ethics Committee (IEC), Government Medical College, Nagpur-440003, Maharashtra, India ECR/43/Inst/MH/2013/RR-19	Dr. Ashok Kumar Diwan
HCG Cancer Centre, Kalinga Rao Road, Bengaluru No 8, HCG Towers,P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru, Karnataka- 560027	HCG Central Ethics Committee, HCG Tower, #8, Kalinga Rao Road, Sampangi Ram Nagar, Bangalore-560027 ECR/386/Inst/KA/2013/RR-19	Dr. Satheesh CT
HCG Cancer Centre, Holy Cross Road, IC Colony, Off Borivali-Dahisar Link Rd, Borivali West, Mumbai, Maharashtra-400092	HCG Cancer Centre Institutional Ethics Committee HCG Cancer Centre holy Cross Road, Ic Colony Off Borivali Dahisar Link Road, Borivali, West Mumbai, Maharashtra-400092 ECR/1468/Inst/MH/2020	Dr. Indoo Ambulkar
HCG Manavata Cancer Centre, Behind Shivang Auto, Mumbai naka, Nashik 422002, Maharashtra, India	Manavata Clinical Research Institute Ethics Committee, HCG Manavata Cancer Centre, Behind Shivang Auto, Mumbai Naka, Nashik-422002, Maharashtra, India ECR/500/Inst/MH/2013/RR-20	Dr. Rajnish Nagarkar
Maulana Azad Medical College, Lok Nayak Hospital, New Delhi-110002, Delhi, India	Institutional Ethics Committee, Maulana Azad Medical College, 3rd Floor, Room No. 306B, Bahadur Shah, Zafar Marg, New Delhi-110002, India ECR/329/Inst/DL/2013/RR-19	Dr. Kishore Singh
Regional Cancer Centre – Medical College Campus, Post bag No.2417, Trivandrum, Kerala	Human Ethics Committee, Regional Cancer Centre, First Floor, Medical College Campus, Trivandrum, Kerala-695011 ECR/21/Inst/Ker/2013/RR19	Dr. Rona Joseph P

File No. CT/104/21-DCG(I)

Yashoda Hospitals, Raj Bhavan Road, Somajiguda, Hyderabad-500082, Telangana State, India	Institutional Ethics Committee, Yashoda Academy of Medical Education & Research, Yashoda Group of Hospitals, Yashoda Hospital, Behind Hari Hara Kalabhavan, Alexander Road, Secunderabad 500003, Telangana State ECR/49/AP/Inst/2013/RR-19	Dr. Nikhil Suresh Ghadyalpatil